Mounting evidence suggests that we could exploit the IFN pathway therapeutically because IFNs both stimulate an antitumor immune response and have a direct effect on cancer cell proliferation and survival.19 However, researchers have encountered many obstacles when developing agents to stimulate this pathway, and there is no effective agent currently used clinically. This evidence concerns the gene IFNA1 and cancer.